Earnings ·
Mobia Medical reported second quarter 2026 revenue of $13.5 million, a 102% increase from the prior year period…
MOBIMobia Medical, Inc.
Mobia Medical reported second quarter 2026 revenue of $13.5 million, a 102% increase from the prior year period, driven by higher adoption of its Vivistim System. The company achieved an 83.2% gross margin and incurred a net loss of $21.0 million, or $1.10 per share, compared to a $10.5 million loss in the previous year. Operating expenses rose 83% to $29.2 million due to increased commercial personnel costs and development spending. The filing notes the completion of an initial public offering that raised approximately $134.0 million in net proceeds, bringing cash and equivalents to $177.1 million as of June 30, 2026. Additionally, two-year follow-up data for its VNS-REHAB therapy was published in Neurology®, demonstrating durable improvements in motor function. The company provided full year 2026 revenue guidance between $54.0 million and $56.0 million. Mobia Medical is a medical device company developing implantable vagus nerve stimulation solutions for stroke recovery.